Bay Street News, February, 2024

Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE®(pegcetacoplan injection) and $91 million for EMPAVELI®(pegcetacoplan) Strong […]

2023 net revenues increased 4.5% to $1.05 billion, compared to 2022 2023 net income of $51 million or $0.18 per […]

THE WOODLANDS, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today the […]

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving […]

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase […]

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), […]

DETROIT, Feb. 27, 2024 (GLOBE NEWSWIRE) — DT Midstream, Inc. (NYSE: DTM) announced that its 2024 Annual Meeting of Stockholders […]

MINNEAPOLIS and LONDON, Feb. 27, 2024 (GLOBE NEWSWIRE) — Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management […]

LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive […]

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Marimaca Copper Corp. (“Marimaca Copper” or the “Company”) (TSX: MARI) announces […]